Photo Credit: wildpixel
The following is a summary of “Effect of hemoglobin, albumin, lymphocyte, and platelet score on prognosis in intermediate-risk endometrial cancer according to molecular-based classification,” published in the October 2024 issue of Obstetrics and Gynecology by Ozdemir et al.
People with endometrial cancer (EC), a disease of the uterine lining, are categorized by molecular subtypes, polymerase-epsilon (POLE) mutation, mismatch repair deficiency (MMRd), non-specific molecular profile (NSMP), and p53 mutation. Those in the intermediate-risk group (MMRd and NSMP) have variable outcomes, creating a need for better prognostic tools.
Researchers conducted a retrospective study to explore the relationship between molecular subtypes of EC and the hemoglobin, albumin, lymphocyte, and platelet (HALP) score in predicting prognosis.
They included 150 individuals diagnosed with EC (2014 and 2024). Participants were divided into 3 groups, people with POLE mutation (group 1), those with MMRd or NSMP (group 2), and those with p53 mutation (group 3). Group 2 participants were further divided into low and high HALP score groups based on a cut-off value of 33.735, identified using Youden’s index (0.306, sensitivity 61.86%, specificity 68.75%).
The results showed that people with intermediate-risk EC and low HALP scores had a 5-year OS rate of 75.4%, compared with 91.5% for those with high HALP scores (P=0.008). For progression-free survival (PFS), individuals with low HALP scores had a 5-year rate of 86%, while those with high HALP scores had a rate of 94.4% (P=0.089). The HALP score was effective at predicting OS but less reliable for PFS in intermediate-risk cases.
They concluded that HALP score was a helpful tool for predicting OS in people with intermediate-risk EC but was less effective for PFS.
Source: obgyn.onlinelibrary.wiley.com/doi/10.1111/jog.16103
